Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting

FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval

August 10, 2016 12:50 PM EDT

Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:

... More

FDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - Analyst

August 10, 2016 11:14 AM EDT

Leerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for treatment of chemo induced nausea and vomiting.

Analyst Jason Gerberry commented today: We are still reviewing the package insert, but Sustol... More